On ECHEMI
Home > Drugs > Erythromycin Enteric-coated Tablets

Erythromycin Enteric-coated Tablets

Function and Efficacy

This product belongs to the macrolide antibiotics. It has antibacterial activity against Staphylococcus (except methicillin-resistant strains), all groups of streptococci and Gram-positive bacilli. Neisseria, Haemophilus influenzae, Bordetella pertussis, etc. are also sensitive to this product. This product also has antibacterial effects on various anaerobic bacteria except Bacteroides fragilis and Fusobacterium. It also has inhibitory effects on Legionella, Campylobacter fetus, some spirochetes, Mycoplasma pneumoniae, Rickettsia and Chlamydia. This product is an antibacterial agent, but it also has a bactericidal effect on some bacteria at high concentrations. It can penetrate the bacterial cell membrane and reversibly bind to the 50S subunit of the bacterial ribosome near the donor site ("P" site), blocking the transfer RNA (t-RNA) from binding to the "P" site, and also blocking the self-acceptor site ("A" site) of the polypeptide chain.

Ingredients

The main ingredient of this product is erythromycin base.

Name Description Content CAS NO. Manufacturer
ErythromycinIngredients

This product belongs to the macrolide antibiotics. It has antibacterial activity against Staphylococcus (except methicillin-resistant strains), all groups of streptococci and Gram-positive bacilli. Neisseria, Haemophilus influenzae, Bordetella pertussis, etc. are also sensitive to this product. This product also has antibacterial effects on various anaerobic bacteria except Bacteroides fragilis and Fusobacterium. It also has inhibitory effects on Legionella, Campylobacter fetus, certain spirochetes, Mycoplasma pneumoniae, Rickettsia and Chlamydia. This product is an antibacterial agent, but it also has a bactericidal effect on certain bacteria at high concentrations. It can penetrate the bacterial cell membrane and reversibly bind to the 50S subunit of the bacterial ribosome near the donor site ("P" site), blocking the transfer RNA (t-RNA) from binding to the "P" site, and also blocking the self-acceptor site ("A" site) of the polypeptide chain.

More
114-07-8 43

Appearance

This product is enteric-coated tablets or enteric-coated film-coated tablets. After removing the coating, it appears white or off-white.

Indication

1 This product can be used as an alternative to penicillin allergy for the following infections: acute tonsillitis, acute pharyngitis, sinusitis caused by hemolytic streptococci, pneumococcus, etc.; scarlet fever and cellulitis caused by hemolytic streptococci; diphtheria and diphtheria carriers; gas gangrene, anthrax, tetanus; actinomycosis; syphilis; listeriosis, etc. 2 Legionnaires' disease. 3 Mycoplasma pneumonia. 4 Chlamydia pneumoniae pneumonia. 5 Urinary and reproductive system infections caused by Chlamydia and Mycoplasma. 6 Chlamydia trachomatis conjunctivitis. 7 Neisseria gonorrhoeae infection. 8 nbs

Usage and Dosage

Oral administration: 1-2g per day for adults, divided into 3-4 doses. Patients with Legionnaires' disease, 2-4g per day, divided into 4 doses. Children, 30-50mg/kg per day, divided into 3-4 doses.

Adverse Reactions

1 Gastrointestinal reactions include diarrhea, nausea, vomiting, upper and middle abdominal pain, pain in the mouth and tongue, decreased appetite, etc., and the incidence is related to the dose. 2 Hepatotoxicity is rare. Patients may experience fatigue, nausea, vomiting, abdominal pain, fever, abnormal liver function, and occasionally jaundice. 3 When used in large doses (≥4g/day), especially in patients with liver or kidney diseases or elderly patients, hearing loss may occur, which is mainly related to the high blood drug concentration (12mg/L). Most of them can be recovered after drug discontinuation. 4 Allergic reactions are manifested as drug fever, rash, eosinophilia, etc., with an incidence of about 0.5% to 1%. 5 Others, occasionally arrhythmia, oral or vaginal nausea

Precautions

Patients who are allergic to this product or other macrolide drugs are contraindicated.

Special Population Medication

Precautions for children: Not clear. Precautions for pregnancy and lactation: Use with caution in pregnant and lactating women. A dosage of less than 0.05% is excreted into breast milk. Although there are reports that it has little effect on infants, it is still necessary to consider whether to stop breastfeeding. Precautions for the elderly: If there is no significant change in pharmacokinetics in the elderly, there is no need to adjust the dose.

Drug Interactions

1. Erythromycin can inhibit the metabolism of carbamazepine, leading to an increase in the latter's blood concentration and toxic reactions. 2. Erythromycin has an antagonistic effect on chloramphenicol and lincomycin, so their co-use is not recommended. 3. Patients who have been taking warfarin for a long time may experience a prolonged prothrombin time when using erythromycin, thereby increasing the risk of bleeding. Elderly patients should pay special attention. When the two must be used together, the dose of warfarin should be appropriately adjusted, and the prothrombin time should be closely monitored. 4. Antibacterial agents can interfere with the bactericidal efficacy of penicillin. Therefore, when a rapid bactericidal effect is required, such as in the treatment of meningitis, the two should not be used together. 5. Except for dihydroxypropylphylline, erythromycin and xanthines

Storage

Sealed, store in a dry place.

Packaging Specification

0.125 g (125,000 units)

Validity Period

36 months

Manufacturer

Gansu Hexi Pharmaceutical Co., Ltd.

  • Founded in:

    2004-11-12
  • Address:

    No. 123 East Street, Ganzhou District, Zhangye City
  • Tax NO.:

    91620702225250908N
  • Registered Funds:

    30 million yuan
  • Website:

  • Email:

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.